circadian clock is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2026-06-15. Where a claim depends on a specific study, the study is described rather than over-claimed.
Regulatory and sporting contexts treat SR9009 as a prohibited substance in many elite competitions. Its presence on banned lists reflects concerns about performance enhancement and unknown long-term safety. Analytical chemists have developed methods to detect the parent compound and its metabolites in urine and blood. Literature discussions distinguish between in vitro potency, animal pharmacology, and anecdotal human reports. The latter are difficult to verify because products sold online may lack purity or contain different compounds.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms, lipid metabolism, and inflammatory gene expression. In cell and animal experiments, SR9009 alters transcription of clock-controlled genes and metabolic pathways. The compound is not a hormone and does not resemble classical steroid structures. Its activity depends on binding to the ligand-binding domain of REV-ERB, where it can modify corepressor recruitment.
Preclinical reports have linked SR9009 to improved endurance and altered energy expenditure in rodents. Such findings have prompted interest in whether REV-ERB activation can influence skeletal muscle metabolism. However, the reported effects depend on dose, route, and experimental model, and replication across laboratories is limited. Human trials have not established comparable outcomes, so claims about exercise performance remain speculative. The absence of controlled human data is a central limitation in interpreting these observations.
The mechanism of action involves binding to REV-ERB receptors and recruiting corepressor complexes, which represses target gene transcription. This contrasts with many nuclear receptor agonists that activate transcription. Downstream effects may include changes in autophagy, mitochondrial biogenesis, and lipid handling, but the precise pathways remain an active area of study. Whether these molecular events translate into meaningful physiological effects in humans is unresolved. Most evidence comes from cultured cells and rodent models rather than human participants.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic REV-ERB agonist | Binds REV-ERBα and REV-ERBβ in preclinical models |
| Molecular formula | C20H24ClN3O4S | Reported for the parent compound |
| CAS Registry Number | 1379686-30-2 | Common identifier in chemical databases |
| Appearance | Off-white to pale yellow solid | Typical research chemical solid |
| Solubility | Soluble in DMSO and ethanol; low in water | Class: small organic molecule |
Quality control for research materials includes identity confirmation by nuclear magnetic resonance and purity assessment by high-performance liquid chromatography. Mass spectrometry provides molecular weight confirmation and can detect related impurities. Purchasers should request a certificate of analysis that lists lot-specific data. Online products advertised for human use often lack such documentation. Distinguishing legitimate research material from mislabeled or contaminated samples is a recurring challenge in independent testing, and independent laboratories may use orthogonal methods to verify identity.
Detection of SR9009 in biological samples usually relies on liquid chromatography coupled to tandem mass spectrometry. This approach separates the compound from matrix components and identifies it by mass transitions. Because SR9009 can undergo metabolism, laboratories often look for both parent drug and specific metabolites. Sample preparation may involve protein precipitation or solid-phase extraction. Method validation examines sensitivity, carryover, and interference from related substances, and reference standards are required for accurate calibration.
Regulatory status varies by country and intended use. Major drug agencies have not granted marketing authorization for SR9009 as a medicine, and it is not listed as a controlled substance in many jurisdictions. It is often sold as a research chemical, a category that may fall outside pharmaceutical manufacturing rules. Buyers should verify local laws and supplier documentation, including certificates of analysis. The lack of standardized quality controls raises concerns about identity, purity, and actual content in products marketed online.
In laboratory settings, SR9009 is commonly identified by its molecular structure and its interaction with REV-ERB receptors. Vendors may list it under synonyms such as Stenabolic or REV-ERB agonist, but those names do not define purity or identity. Analytical confirmation typically uses high-performance liquid chromatography with ultraviolet detection or liquid chromatography–mass spectrometry. A reference standard is needed to compare retention time and mass spectrum, because the compound can be confused with related research chemicals.
Preclinical reports describe effects on exercise endurance, mitochondrial content, and lipid profiles in rodents, but these findings come from specific experimental conditions. Many studies use high doses or delivery methods that may not translate directly to human use. SR9009 has been reported to have low oral bioavailability and a short half-life, which complicates interpretation of oral dosing studies. It is not established as safe or effective for any indication. Literature discussions often separate its pharmacological mechanism from unverified claims made in fitness and supplement markets.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not an approved medicine and has no established human therapeutic use. The compound appears in scientific literature as a tool for probing circadian and metabolic regulation. Online sellers often label it as a research chemical, sometimes using the nickname Stenabolic. Its chemical identity is distinct from selective androgen receptor modulators, stimulants, and peroxisome proliferator-activated receptor delta agonists. Researchers use it mainly in cell and animal experiments.
At the molecular level, SR9009 binds REV-ERBα and REV-ERBβ and alters their repressive activity on target genes. These nuclear receptors help regulate the circadian clock, lipid synthesis, glucose metabolism, and inflammatory pathways. By changing transcription, the compound can shift the timing or magnitude of downstream metabolic processes in model systems. It does not act through androgen receptors or adenosine receptors, which distinguishes it from several substances sold for athletic performance. Whether the same transcriptional changes occur in humans at tolerable exposures remains an open question because controlled human studies are lacking.
SR9009 is often grouped with compounds studied for circadian and metabolic regulation rather than with classical anabolic steroids. Its interactions with nuclear receptors differ from those of androgen receptor ligands, and its proposed mechanisms involve transcriptional control rather than direct hormone signaling. Some sources classify it as a metabolic modulator because of observed effects on energy utilization. The distinction matters for regulation and for interpreting research results across different compound classes.
SR9009 is a synthetic small molecule developed as a REV-ERB agonist. It binds to REV-ERBα and REV-ERBβ, nuclear receptors that help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, the compound alters lipid and glucose handling and influences skeletal muscle oxidative capacity. Its exact effects in humans remain largely uncharacterized because controlled clinical trials have not been reported. The molecule is frequently described in preclinical literature as a metabolic modulator.
Research interest in SR9009 grew from studies showing improved running endurance in mice after short treatment periods. Those experiments linked the compound to increased mitochondrial content and fatty acid oxidation in muscle, but the findings come from animal models and specific dosing schedules. Independent replication has been limited, and the pathways connecting REV-ERB activation to exercise performance are still being mapped. Whether similar responses occur in humans is an open question.
2 Er(s) + 3 F2(g) → 2 ErF3(s) [pink] 2 Er(s) + 3 Cl2(g) → 2 ErCl3(s) [violet] 2 Er(s) + 3 Br2(g) → 2 ErBr3(s) [violet] 2 Er(s) + 3 I2(g) → 2 ErI3(s) [violet] Erbium dissolves readily in dilute sulfuric acid to form solutions containing hydrated Er(III) ions, which exist as rose red [Er(H2O)9]3+ hydration complexes:
==== Regular ==== 22 SAS is under the operational command of the Director Special Forces (DSF), a major-general grade post. Previously ranked as a brigadier, the DSF was promoted from brigadier to major-general in recognition of the significant expansion of the United Kingdom Special Forces (UKSF).
In a study looking at gene polymorphisms of GPX1 and other oxidative stress genes in relation to prevalence of Type 2 diabetes mellitus, Banerjee, et al., found that while no association was found in expression of most GPX1 polymorphisms and risk of Type 2 diabetes mellitus, having the C allele of GPX1 led to a 1.362 times higher risk of the disease, highlighting the importance of finding individuals in the population with this gene variant to help treat them early on. Recent work by Alan M. Diamond and colleagues has shown that allelic variations of GPX1, like the codon 198 polymorphism that results in leucine or proline and an increase in alanine repeat codons, can result in different localization levels in MCF-7 human breast carcinoma cells. For instance, the allele expressing the leucine-198 polymorphism and 7 alanine repeats generates GPX-1 localization that is disproportionately in the cytoplasm as compared to other allelic variants. To further understand the effects of these variants on GPX-1 function, mutant GPX-1 with mitochondrial localization sequences were generated and the GPX-1 infused cells were analyzed for their response to oxidative stress, energy metabolism and cancer-associated signaling molecules. Ultimately, GPX-1 variants heavily influenced cellular biology, suggesting that different GPX-1 variants affect cancer risk differently.
==== MeSH E05.318.760 – epidemiologic study characteristics ==== MeSH E05.318.760.500 – epidemiologic studies MeSH E05.318.760.500.500 – case-control studies MeSH E05.318.760.500.500.500 – retrospective studies MeSH E05.318.760.500.750 – cohort studies MeSH E05.318.760.500.750.500 – longitudinal studies MeSH E05.318.760.500.750.500.350 – follow-up studies MeSH E05.318.760.500.750.500.650 – prospective studies MeSH E05.318.760.500.875 – cross-sectional studies MeSH E05.318.760.500.950 – seroepidemiologic studies MeSH E05.318.760.500.950.375 – hiv seroprevalence MeSH E05.318.760.535 – clinical trials MeSH E05.318.760.535.200 – clinical trials, phase i MeSH E05.318.760.535.210 – clinical trials, phase ii MeSH E05.318.760.535.220 – clinical trials, phase iii MeSH E05.318.760.535.230 – clinical trials, phase iv MeSH E05.318.760.535.365 – controlled clinical trials MeSH E05.318.760.535.365.500 – randomized controlled trials MeSH E05.318.760.535.500 – multicenter studies MeSH E05.318.760.550 – feasibility studies MeSH E05.318.760.565 – intervention studies MeSH E05.318.760.750 – pilot projects MeSH E05.318.760.875 – sampling studies MeSH E05.318.760.900 – twin studies
Sources: en.wikipedia.org
=== Other vapors === Although both oxygen and water vapor represent the most studied permeants in food packaging applications, other gases such as carbon dioxide (CO2) and nitrogen (N2) have also great relevance in the preservation of food products. In fact, N2 and CO2 have been employed in modified atmosphere packaging (MAP) technology, to establish the correct conditions inside the package's headspace to lessen food spoiling.
The number of people living in urban areas grew by 31.2% between 1991 and 2001. In 2001, over 70% lived in rural areas. The level of urbanisation increased further from 27.81% in the 2001 census to 31.16% in the 2011 census. The overall population growth rate slowed because rural growth declined sharply after 1991. In the 2011 census, there were 53 million-plus urban agglomerations in India, among them Mumbai, Delhi, Kolkata, Chennai, Bangalore, Hyderabad and Ahmedabad, in decreasing order by population.
=== Study of human emotions === At the beginning of her career, Barrett's research focused on the structure of affect, having developed experience-sampling methods and open-source software to study emotional experience. Barrett and members at the Interdisciplinary Affective Science Laboratory study the nature of how the brain creates the mind broadly from social-psychological, psychophysiological, cognitive science, and neuroscience perspectives, and take inspiration from anthropology, philosophy, and linguistics. They also explore the relationship between emotion and vision and other psychological phenomena. In 2010, she joined the psychology faculty at Northeastern University. Before that, she held academic positions at Boston College (1996-2010) and was an assistant professor of clinical psychology at Pennsylvania State University. Notable doctoral students of Barrett's include Tamlin Conner. Her research has focused on the main issues in the science of emotions such as:
Carbonization, the complete pyrolysis of organic matter, which usually leaves a solid residue that consists mostly of elemental carbon. Methane pyrolysis, the direct conversion of methane to hydrogen fuel and separable solid carbon, sometimes using molten metal catalysts. Hydrous pyrolysis, in the presence of superheated water or steam, producing hydrogen and substantial atmospheric carbon dioxide. Dry distillation, as in the original production of sulfuric acid from sulfates. Destructive distillation, as in the manufacture of charcoal, coke and activated carbon. Charcoal burning, the production of charcoal. Tar production by destructive distillation of wood in tar kilns. Caramelization of sugars. High-temperature cooking processes such as roasting, frying, toasting, and grilling. Cracking of heavier hydrocarbons into lighter ones, as in oil refining. Thermal depolymerization, which breaks down plastics and other polymers into monomers and oligomers. Ceramization involving the formation of polymer derived ceramics from preceramic polymers under an inert atmosphere. Catagenesis, the natural conversion of buried organic matter to fossil fuels. Flash vacuum pyrolysis, used in organic synthesis.
== Environmental Impact == Parcel to pallet sized insulated shipping containers have historically been single-use products due to the low-cost material composition of EPS and water-based gel packs. The insulation material typically finds its way into landfill streams as it is not readily recyclable in the United States. The development of reusable high-performance shipping containers have been shown to reduce packing waste by 95% while also contributing significant savings to other environmental pollutants.
Sources: en.wikipedia.org
SR9009 is a synthetic small molecule studied as an agonist of the REV-ERB nuclear receptors. It is not an approved medicine, and its effects in humans are not well characterized.
No. It is a synthetic ligand that binds nuclear receptors, not a steroid or peptide hormone. Its activity depends on receptor binding rather than endocrine secretion.
Clinical evidence is limited. Most published data come from cell and animal experiments. Human safety and efficacy remain uncertain.
It is a synthetic compound that acts as an agonist at REV-ERBα and REV-ERBβ. It is used mainly as a research chemical to study circadian and metabolic pathways. It is not approved for human therapeutic use.